Growth hormone secretagogues: the peptides that turn your own growth hormone back up

Somewhere after your twenties, your body turns a dial down. Growth hormone — the signal behind deep sleep, easy recovery, and a body that holds muscle and sheds fat without much of a fight — starts coming out in smaller pulses every year. You don’t get a memo. You just notice the recovery that used to be free, and a middle that didn’t used to be there.

Growth hormone secretagogues are a class of peptides built around one idea: turn that dial back up. Not by injecting the hormone out of a bottle — by asking the gland you already own to fire the way it did ten years ago. Four names keep coming up together — CJC-1295, ipamorelin, sermorelin, and tesamorelin — because they all do that one thing. And one of them has already proven, in a real FDA trial, that it does something you’d actually want.

What turning the dial back up could do for you

Start with why anyone wants more growth hormone in the first place. In an adult, growth hormone and the IGF-1 it drives sit behind three things men feel slipping: how the body holds lean muscle and burns fat, how fast it repairs itself, and how deeply it sleeps. Push those back toward where they were at thirty and you’re chasing the core of what people mean by the longevity dream — not living forever, just running your own repair machinery closer to full.

Here’s the part that lifts this above wishful thinking. One peptide in the class has real, measured proof. In a 2007 trial of 412 people, tesamorelin dropped the deep, dangerous fat packed around the organs by about 15 percent, while the placebo group’s crept up 5 percent. A separate 2012 trial of the same class — the GHRH analog tesamorelin — nudged cognition in the right direction in older adults. Those aren’t animal hints. They’re humans, placebos, and numbers that moved.

The catch — and it’s the honest one — is that those wins belong to specific peptides in specific groups, not to the whole class at once. Which is exactly why the four names aren’t interchangeable, and why each has its own page: CJC-1295, ipamorelin, sermorelin, and tesamorelin.

Two doors into the same room

All four peptides press the same button — the pituitary’s release of growth hormone — but they reach it two different ways. The split is worth understanding, because it’s why they get stacked.

Three of them copy GHRH, the natural release signal your brain sends the pituitary: CJC-1295, sermorelin, and tesamorelin. Sermorelin was built straight from GHRH — it’s the working front end of that hormone. They walk up to the gland and give the same order your own body gives, just louder and for longer.

Ipamorelin takes the other door. It mimics ghrelin — yes, the hunger hormone — which happens to hit a second receptor on the same gland that also triggers growth hormone. When Novo Nordisk chemists designed it in the 1990s, the trick was doing that cleanly: a pulse of growth hormone without the stress-hormone noise the older members of its family dragged along.

That’s why the classic pairing is CJC-1295 with ipamorelin — one from each door. Two levers on the same gland, a bigger and cleaner pulse than either pulls alone. Neat on paper. Whether the pair changes anything you’d feel is a separate question, and it’s the one the deep-dive pages take apart.

Same mechanism, four different evidence files

Here’s where the shared label stops being useful. Growth hormone secretagogue tells you how these peptides work. It says nothing about how well any one of them is proven — and there, the four split hard.

Tesamorelin is the only one holding a live FDA approval today. Even then, it covers just one narrow use: a type of fat build-up in people with HIV. Everything past that is off-label hope. CJC-1295 has a single well-run human trial from 2006 — growth hormone up for days, safe at the doses tested — then twenty years of quiet. Ipamorelin’s one clinical-scale human trial tested a hospital use, nothing to do with performance. The result came back null — no real edge over placebo. Sermorelin has genuine FDA history but a thin file in healthy adults, some of it built on a slightly different molecule than the one sold.

So the honest read is a split decision. The mechanism is real and shared. The proof is uneven and peptide-specific. A 2026 review of the whole class lands in the same place: promising biology, real open questions about dosing, stacking, and whether any of it pays off over years. That gap isn’t a reason to walk away. It’s the reason to be precise about which peptide you’re actually talking about.

Where the regulators landed

The regulatory picture splits the same way the evidence does, so keep it simple.

CJC-1295 and ipamorelin have already been in front of the FDA’s compounding advisory committee. Both were reviewed in late 2024, and the committee voted against adding either to the list of substances pharmacies are cleared to compound. That’s not the same as still waiting in the queue — their review already happened, and the answer, for now, was no. Sermorelin sits more comfortably: its active ingredient cleared the FDA decades ago as a drug called Geref, so it runs under established compounding rules rather than the new-substance review. Tesamorelin is a finished, approved drug, which means a physician can prescribe it off-label, but the rules sharply limit compounding a copy of it. What that committee actually decides, and what it doesn’t, is walked through in what a PCAC review actually is.

One line for anyone who competes. The entire class is prohibited by WADA, in and out of competition — check the current code on the day, because these lists move.

What a legitimate version looks like

Line all four up and the real problem comes into focus. It was never the biology. Nudging your own growth hormone back toward where it sat a decade ago is a genuinely good idea, and at least one peptide in the class has the human data to back a piece of it. The trouble is the menu it’s sold from — four names on a research-chemical site, no way to know which molecule is in the vial, at what strength, or whether it’s the form anyone ever studied.

A physician erases that in one move. The right peptide picked for your actual goal — fat, recovery, the GH axis itself — instead of the one a forum recommended. A US-licensed pharmacy compounding the real thing. A test on every batch before it reaches you. That’s the difference between guessing and knowing, and it’s the whole reason Wolverine Health is being built.

It can’t open until the regulation catches up, and that’s the honest reason it hasn’t yet. Leave your email. The day any of these four stops being a gamble off a menu and becomes a protocol a physician picks for you, we’ll send a single note — no sooner.